Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 6/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 3/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25106845 | 0.93 | NR1H2 (0.32) | NR1H2NR1H3KCNH2RORCCA12 | |
| SCHEMBL25106951 | 0.90 | NR1H2 (0.39) | NR1H2NR1H3KCNH2RORCNPC1 | |
| SCHEMBL18819839 | 0.87 | PTGS2 (0.37) | NR1H2NR1H3KCNH2RORCCA12 | |
| SCHEMBL25106814 | 0.86 | NR1H2 (0.33) | NR1H2NR1H3KCNH2RORCPTGS2 | |
| SCHEMBL25106846 | 0.84 | NR1H2 (0.39) | NR1H2NR1H3KCNH2RORC | |
| SCHEMBL18819855 | 0.83 | NPC1 (0.35) | NR1H2NR1H3KCNH2RORCCA12 | |
| SCHEMBL25106815 | 0.82 | POLB (0.40) | NR1H2NR1H3RORCNPC1RAB9A | |
| SCHEMBL25106842 | 0.81 | NR1H2 (0.32) | NR1H2NR1H3 | |
| SCHEMBL19806353 | 0.81 | KCNH2 (0.33) | KCNH2RORCNPC1RAB9APTGS2 | |
| SCHEMBL25106949 | 0.80 | LMNA (0.34) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230060425-A1 | FUSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230060425-A1 | FUSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES | DDT, CBR1, CBR3 | NR1H2 1088/4885NR1H3 1362/4885KCNH2 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.